Drug Discovery World

SEPTEMBER 13, 2023

27% of patients with non-vaccinal SARS-COV-2 positive serology corresponded to the previously described psychotic disorder subgroup associating HERV-W expression. times more than the control group.

Protein Expression 130

Protein Expression Clinical Trials Hospitals Trials 130

Drug Discovery World

FEBRUARY 9, 2023

A Phase III clinical trial has produced promising results for a cancer vaccine targeting patients with a new or recurrent glioblastoma. Trial data show that 13% of patients receiving the vaccine survived the five years, compared to 5.7% receiving existing treatments. Published online November 17, 2022. doi:10.1001/jamaoncol.2022.5370

Clinical Trials 130

Clinical Trials Vaccine Trials Treatment 130

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. Why are challenge trials becoming more popular?

Vaccine 132

Vaccine Trials Disease Virus 132

The Pharma Data

SEPTEMBER 30, 2021

As one among the leading global vaccines companies, we still bring options which help protect people’s health round the world,” said Michael Greenberg, MD, MPH, Medical Head, Sanofi Pasteur North America. “As A study conducted from 2014 to 2015 showed 72% of infants hospitalized for RSV were previously healthy with no underlying conditions.3.

Vaccine 52

Vaccine Research Virus Hospitals 52

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S. Ugur Sahin, M.D.,

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

MARCH 14, 2023

QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing. QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing.

Vaccine 40

Vaccine Virus Hospitals Trials 40

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Anderson most recently served as Vice President and Chief Scientific Officer for Bacterial Research and Hospital within the Vaccine R&D organization.

Vaccine 40

Vaccine Research Doctors Laboratories 40

Drug Target Review

DECEMBER 28, 2023

In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. Involving more than 250 investigators based at 19 hospital sites across the UK, the study has analysed genetic signatures in lung tumours, tracking how they have evolved over the past nine years in more than 815 patients.

Bioinformatics 103

Bioinformatics Immune Response DNA Vaccine 103

Drug Discovery World

MAY 6, 2024

A more established Amsterdam-based enterprise is gene therapy company uniQure, developer of etranacogene dezaparvovec, the first gene therapy for haemophilia B, which was approved for use in the US in November 2022 and in the EU in February 2023. The rights for etranacogene dezaparvovec were subsequently sold to CSL Pharmaceuticals.

Drugs 148

Drugs Science Molecular Biology Clinical Trials 148

Drug Discovery World

MAY 25, 2023

The aim of the researchers is to understand the mechanisms that regulate cancer cell proliferation, survival and dissemination; to identify critical components of these pathways as targets for novel cancer therapies; and to help translate this knowledge to patient benefit.

Research 130

Research Virus Drugs Disease 130

The Pharma Data

MARCH 5, 2021

Novartis announced today that it has signed an initial agreement to manufacture the mRNA and bulk drug product for the COVID-19 vaccine candidate CVnCoV from CureVac to aid in the fight against the COVID-19 pandemic. Preparations for the start of production, technology transfer and test runs are already underway.

Vaccine 52

Vaccine Production Biosimilars Hospitals 52

The Pharma Data

JULY 29, 2021

The EUA now provides for the use of baricitinib for treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). percent (24/515) for baricitinib plus remdesivir versus 7.1

Hospitals 52

Hospitals FDA Laboratories Licensing 52

The Pharma Data

MAY 7, 2021

. Pfizer-BioNTech files for US approval of COVID-19 vaccine ( Reuters ) ( NYTimes ) ( Politico ) ( Press ). Covid-19 Vaccines Are Wasted as Special Syringes Run Short ( WSJ ). Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug ( Endpoints ). What happens now?

Vaccine 52

Vaccine Compounding Pharmacies Regulations Drugs 52

The Pharma Data

SEPTEMBER 18, 2020

This week Pharma IQ looks at how the pharma industry is expanding its vaccine manufacturing and testing protocols to ensure the deadly Covid-19 outbreak yields in its spread around the globe. . BioNTech acquires Novartis GMP manufacturing site to expand Covid-19 vaccine production.

Vaccine 52

Vaccine Long-Term Care Facilities Clinical Supply Laboratories 52

Drug Discovery World

NOVEMBER 1, 2022

Ground-breaking therapies . The company said: “As of the 28 September 2022, patients have been dosed with Auceliciclib, and dosing has completed for Cohorts 1 – 5 of the monotherapy dose escalation, and Cohorts 1a, 1b for the combination therapy arms with Temozolomide (TMZ).

Drugs 130

Drugs Science Therapies Clinical Trials 130

The Pharma Data

NOVEMBER 18, 2020

These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. In addition, OBI-833 can elicit a beneficial immune response in NSCLC patients and had rendered some TKI-treated patients a durable stable disease status. Presenter: Ching-Liang Ho MD, et.al.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. Ricks , Lilly chairman and CEO.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

The Pharma Data

AUGUST 28, 2020

The top 10 news stories this week are focused on coronavirus vaccines and treatments, as China is set to move ahead with human testing of a potential vaccine that has been created using insect cells, while AstraZeneca has started a clinical trial of its antibody treatment designed to prevent and also treat symptoms of coronavirus.

FDA Approval 52

FDA Approval Clinical Trials Vaccine FDA 52

The Pharma Data

OCTOBER 19, 2020

.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. among adults 65 years of age or older.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

Drug Discovery World

SEPTEMBER 28, 2022

Whilst we know that AI has been effective in practices such as validating targets that may be suitable to treat a disease, it faces a plethora of significant challenges. There, it is combined with algorithms generated by other hospitals in an identical way to create an optimised algorithm. The simple answer is no.

Pharma Companies 130

Pharma Companies Hospitals Clinical Trials Drugs 130

The Pharma Data

MARCH 17, 2022

The study found that adjuvant treatment with KEYTRUDA significantly improved disease-free survival (DFS), one of the dual primary endpoints, reducing the risk of disease recurrence or death by 24% compared to placebo (hazard ratio [HR]=0.76 [95% CI, 0.63-0.91]; 0.91]; p=0.0014) in patients with stage IB (? “We About EORTC.

Therapies 52

Therapies Clinical Trials Disease Trials 52

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. About maribavir.

FDA 52

FDA Treatment Disease Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 29, 2020

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease. no CMV disease (compared to 2 out of 14 cases in the placebo group).

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

The Pharma Data

FEBRUARY 24, 2022

Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Despite therapies in multiple drug classes, mortality remains high and treatment options for a broader range of patients are needed. The FDA, an agency within the U.S.

FDA Approval 52

FDA Approval FDA Treatment Hospitals 52

The Pharma Data

MAY 27, 2022

Fast Track is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address unmet medical need. Senior Vice President and Chief Development Officer, Internal Medicine and Hospital, Pfizer. “We Pfizer Inc. NYSE: PFE) today announced the U.S.

FDA 52

FDA Treatment Vaccine Therapies 52

The Pharma Data

JULY 22, 2021

NOTE: ADUHELM TM (aducanumab-avwa)injection 100 mg/mL solutionis indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Disease 52

Disease Research Clinical Trials FDA 52

The Pharma Data

SEPTEMBER 17, 2020

This is the focus of vaccines in development and convalescent plasma therapy. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. “As

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. Credit: NIH Right now, many U.S.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. BARCELONA, Spain , Jan. ” Dr.

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

Drug Discovery World

OCTOBER 20, 2022

This is unsurprising – our drug discovery industry does, after all, centre itself around creating initiatives that leave no one behind, from cancer therapies to malaria vaccines. . Overview . According to the International Trade Administration’s market overview, anti-tumour agents brought in the largest sales in 2020 in Japan.

International 130

International Drugs Science Government 130

The Pharma Data

OCTOBER 26, 2020

FDA Approval: Last week the FDA approved Veklury (remdesivir) for the treatment of COVID-19 requiring hospitalization in adults and pediatric patients (12 years of age and older). Testing Therapies, Antivirals and Vaccines. Eli Lilly halted a separate study of its LY-COV555 antibody against COVID-19 in hospitalized patients.

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

Drug Discovery World

APRIL 20, 2023

Symptoms affect the brain, heart, lungs, GI tract and pancreas, are seen equally in vaccinated populations, and sometimes newly emerge after the acute infection has resolved. Alzheimer’s disease), or by initiating a new one. New therapeutics of course depend on an understanding of biological mechanisms. depression).

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

NOVEMBER 17, 2020

17, 2020 (American Heart Association News) — People with obesity – regardless of age – are more likely to be hospitalized with COVID-19 and have higher risks for complications and death, according to new research. adults have obesity, according to the Centers for Disease Control and Prevention. TUESDAY, Nov. More than 42% of U.S.

Hospitals 52

Hospitals Vaccine Virus Disease 52

Creative Biolabs

SEPTEMBER 6, 2022

Researchers at Cincinnati Children’s Hospital Medical Center published a research paper in Nature titled: Pregnancy enables antibody protection against intracellular infection. At the same time, these findings will have far-reaching implications for antibody therapy in other areas. Reference Erickson, J.J.,

Vaccine 52

Vaccine Virus Clinical Trials Disease 52

The Pharma Data

DECEMBER 1, 2020

has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic. The distribution of the vaccine in the U.K. View the full release here: [link].

Vaccine 40

Vaccine Clinical Trials Trials Production 40

The Pharma Data

MARCH 8, 2022

Gunther Hartmann from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn, in cooperation with other members of the cluster of excellence ImmunoSensation2 at the University of Bonn, have shown this in mice. Also, the incidence of severe disease progression was observed to be significantly reduced.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

NOVEMBER 9, 2020

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40